title: Abciximab in carotid stenting for postsurgical carotid restenosis: intermediate results.
abstract: OBJECTIVE
  To report intermediate results of a pilot study in which the glycoprotein IIb/IIIa receptor antagonist abciximab was given to patients during percutaneous carotid stenting for recurrent internal carotid artery (ICA) stenosis. The objective was to prevent procedure-related cerebral embolic events and decrease the incidence of recurrent stenosis.
  
  
  METHODS
  Sixteen patients (9 women; mean age 66.5 years, range 39-78) with severe ICA recurrent stenosis (>80%) underwent balloon angioplasty and stenting. Before the procedure, abciximab was administered intravenously as a bolus (0.25 mg/kg) followed by a 12-hour continuous infusion (10 microg/min).
  
  
  RESULTS
  Fifteen patients received stents (14 Wallstent and 1 Strecker); 1 vessel was dilated with only 50% improvement in luminal diameter. Two stented arteries had residual stenosis (<30%) but satisfactory luminal diameter was achieved in the remaining 13 (81%) arteries. There were no neurological ischemic events during or following the procedure, nor were there any bleeding or peripheral vascular complications. Duplex surveillance studies up to 12 months revealed no significant recurrent stenosis in the treated vessels.
  
  
  CONCLUSIONS
  The administration of abciximab in conjunction with percutaneous revascularization procedures for postsurgical carotid artery stenosis may reduce cerebral ischemic episodes. It may also attenuate restenosis in the treated artery.
authors.affiliation: Department of Vascular Surgery, Sheba Medical Center, Tel Aviv University, Israel. jschneid@netvision.net.il
authors.forename: J
authors.initials: J
authors.lastname: Schneiderman
authors.forename: B
authors.initials: B
authors.lastname: Morag
authors.forename: A
authors.initials: A
authors.lastname: Gerniak
authors.forename: U
authors.initials: U
authors.lastname: Rimon
authors.forename: D
authors.initials: D
authors.lastname: Varon
authors.forename: U
authors.initials: U
authors.lastname: Seligsohn
authors.forename: A
authors.initials: A
authors.lastname: Shotan
authors.forename: R
authors.initials: R
authors.lastname: Adar
mesh_terms: D000077284:Abciximab; D000328:Adult; D000368:Aged; D000800:Angioplasty, Balloon; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002343:Carotid Artery, Internal; D016893:Carotid Stenosis / Q000150:complications / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy*; D016894:Endarterectomy, Carotid; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D020766:Intracranial Embolism / Q000209:etiology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D010976:Platelet Count; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011859:Radiography; D012008:Recurrence; D015607:Stents
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab